Study guide

11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

Key Takeaways Explain This Topic AI

USP <800> governs the handling of Hazardous Drugs (HDs) listed by NIOSH across receipt, storage, compounding, administration, and disposal to protect personnel and the environment.

Containment Secondary Engineering Controls (C-SECs) for HD compounding must be physically separated, externally vented, and maintained under negative pressure between 0.01 and 0.03 inches of water column.

Non-sterile HD compounding C-SECs require a minimum of 12 ACPH, while sterile HD compounding C-SECs require a minimum of 30 ACPH.

Compounding personnel must wear two pairs of chemotherapy-tested gloves complying with ASTM D6978, with the outer pair being sterile when compounding sterile HD preparations.

Decontamination and cleaning of HD areas requires a mandatory 4-step sequence: Deactivation, Decontamination, Cleaning, and Disinfection (for sterile areas).

Last updated: July 2026

11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & PPE

MPJE Core Concept: USP General Chapter <800> defines worker and environmental protection standards across the entire life cycle of Hazardous Drugs (HDs) . Unlike USP <795> and <797> which focus on patient safety, USP <800> focuses on occupational exposure prevention . Key MPJE test points include C-SEC negative pressure ranges , air change per hour (ACPH) rules , ASTM D6978 chemotherapy gloves , and the 4-step decontamination workflow .

Scope & NIOSH Hazardous Drug Categorization

USP <800> applies to all healthcare personnel who receive, store, compound, dispense, administer, or dispose of hazardous drugs. The chapter adopts the National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, which categorizes HDs into three groups:

Group 1: Antineoplastic drugs (e.g., cisplatin, cyclophosphamide, fluorouracil, vincristine).

Group 2: Non-antineoplastic hazardous drugs meeting one or more NIOSH toxicity criteria (e.g., spironolactone, carbamazepine, divalproex).

Group 3: Drugs that primarily pose reproductive risk to male or female personnel (e.g., misoprostol, dutasteride, finasteride).

Entity Assessment of Risk (AoR)

An entity (pharmacy/hospital) may perform an Assessment of Risk (AoR) for Group 2, Group 3, or final dosage forms of Group 1 HDs to define alternative handling strategies, provided the HDs do not require manipulation other than counting or packaging. If no AoR is performed, all HDs must be handled strictly according to full USP <800> containment rules.

Engineering Controls Architecture (C-PECs, C-SECs, C-SCAs)

USP <800> mandates containment engineering controls specifically designated with a "C-" prefix to isolate HD contaminants:

1. Containment Primary Engineering Control (C-PEC)

A ventilated device designed to minimize worker exposure during HD handling:

For Sterile HD Compounding: Class II Biological Safety Cabinet (BSC Type A2, B1, or B2) or Compounding Aseptic Containment Isolator (CACI). Must be externally vented .

For Non-Sterile HD Compounding: Class I BSC, Class II BSC, or Containment Ventilated Enclosure (CVE / powder hood). Must be externally vented (or, as a strict exception for non-sterile compounding only, redundant HEPA filters in series may be permitted where external venting is unavailable).

2. Containment Secondary Engineering Control (C-SEC)

The physical room in which the C-PEC is placed. The C-SEC must meet three strict engineering criteria:

Physical Separation: Must be a dedicated, physically enclosed room separated from non-HD compounding areas.

External Venting: Must be externally vented to the outside atmosphere.

Negative Pressure Differential: Must maintain continuous negative pressure between 0.01 and 0.03 inches of water column (-2.5 to -7.5 Pascals) relative to adjacent areas.

Air Changes Per Hour (ACPH) Requirements

Non-Sterile HD Compounding C-SEC: Minimum 12 ACPH .

Sterile HD Compounding C-SEC (ISO Class 7): Minimum 30 ACPH .

Containment Segregated Compounding Area (C-SCA): Minimum 12 ACPH under negative pressure (0.01 to 0.03 inches w.c.) and externally vented. Used only for low-volume or Category 1 sterile HD compounding (BUD capped at 12 hours room temp / 24 hours refrigerated).

Personal Protective Equipment (PPE) for HD Handling

PPE provides a physical barrier against hazardous drug splashes, aerosols, and surface residue. All PPE used for HD compounding must be disposable and properly discarded as hazardous drug waste.

1. Chemotherapy Gloves

Testing Standard: Gloves must be tested and rated under ASTM D6978 (a standard specifically designed to evaluate permeation by chemotherapy drugs). Standard medical exam gloves tested under ASTM D3578 are unacceptable .

Double Glove Requirement: Personnel must wear TWO pairs of chemotherapy gloves for all HD compounding, administration, spill handling, and disposal.

Sterility: When compounding sterile HDs, the outer pair of chemotherapy gloves must be sterile .

Donning Rules: The inner glove must be worn under the gown cuff; the outer glove must be pulled over the gown cuff.

Replacement Frequency: Gloves must be changed at least every 30 minutes , or immediately if damaged, torn, or contaminated.

2. Isolation Gowns

Gowns must be shown to resist permeation by HDs (laminated, polyethylene-coated or impermeable material).

Must be back-closing , seamless, lint-free, with long sleeves and tight-fitting elastic or knit cuffs.

Gowns must be changed every 2 to 3 hours or immediately after a spill or splash.

3. Shoe & Hair Covers

Double Shoe Covers: Two pairs of shoe covers are required when compounding sterile HDs. Outer shoe covers must be donned before entering the negative-pressure C-SEC and removed when exiting the C-SEC to prevent spreading HD residue to unclassified corridors.

4. Eye, Face & Respiratory Protection

Eye & Face Protection: Full face shield plus goggles must be worn when there is a risk of HD splashes, sprays, or aerosolization (e.g., cleaning C-PEC drain pans, spill cleanup). Standard safety glasses with side shields do NOT provide adequate splash protection.

Respiratory Protection: An N95 respirator protects against solid particulate powders but does not protect against HD vapors. A Powered Air-Purifying Respirator (PAPR) or elastomeric half-mask with P100 filter is mandatory during HD spill cleanup, handling bulk API powders, or servicing C-PEC components.

Mandatory 4-Step Decontamination & Cleaning Workflow

Cleaning HD handling areas requires a strict, sequential 4-step process to neutralize, remove, and disinfect surfaces:

Deactivation: Renders the hazardous drug compound inactive or non-toxic using EPA-registered oxidizers (e.g., sodium hypochlorite / bleach, hydrogen peroxide, or peracetic acid).

Decontamination: Removes inactivated HD residue and chemical deposits from surfaces using sterile water, 70% alcohol, or specialized HD decontamination wipes.

Cleaning: Removes organic and inorganic soil from surfaces using a germicidal detergent.

Disinfection: Destroys vegetative microorganisms (mandatory in sterile compounding areas) using 70% Sterile Isopropyl Alcohol (IPA) .

Summary of Hazardous Drug Engineering Standards

  • Engineering Control Physical Isolation Pressure Requirement Air Change Rate (ACPH) Venting Requirement
  • Non-Sterile HD C-SEC Dedicated Room Negative (-0.01 to -0.03" w.c.) Min 12 ACPH Externally Vented
  • Sterile HD C-SEC (ISO 7) Dedicated Room Negative (-0.01 to -0.03" w.c.) Min 30 ACPH Externally Vented
  • C-SCA (Unclassified Area) Dedicated Room Negative (-0.01 to -0.03" w.c.) Min 12 ACPH Externally Vented

Loading diagram... USP <800> Hazardous Drug Containment & Cleaning Architecture